Search research articles
Contact Us
Filters
Showing results (61-70 of 113) with videos related to
Page
of 12
Sort By:
HIV Clinical Trials
|
February 11, 2003
Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy
Don E Smith, Jeff Hudson, Allison Martin, et al.
Pediatric Neurosurgery
|
December 18, 2023
A Case Report of Infant-Type Hemispheric Glioma with a Novel GAB1-ABL2 Kinase Fusion Treated with Dasatinib
Emery Buckner-Wolfson, Geena Jung, Timothy Kim, et al.
Lung
|
November 8, 2022
Validation and Meaningful Change Thresholds for an Objective Cough Frequency Measurement in Chronic Cough
Jonathan Schelfhout, Allison Martin Nguyen, Surinder S Birring, et al.
European Urology
|
August 7, 2023
Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review
Robert J Motzer, Pratik P Rane, Todd L Saretsky, et al.
Antiviral Therapy
|
March 9, 2005
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy
Jason C Kovacic, Allison Martin, Dianne Carey, et al.
Lancet (London, England)
|
February 14, 2004
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial
Andrew Carr, Cassy Workman, Dianne Carey, et al.
JAMA
|
July 4, 2002
Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial
Andrew Carr, Cassy Workman, Don E Smith, et al.
Metabolism: Clinical and Experimental
|
January 20, 2012
Energy content of weight loss: kinetic features during voluntary caloric restriction
Steven B Heymsfield, Diana Thomas, Corby K Martin, et al.
AIDS (London, England)
|
August 8, 2013
Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy
Allison Martin, Cecilia Moore, Patrick W G Mallon, et al.
European Urology Focus
|
January 10, 2018
The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort
Maxine Sun, Guillermo De Velasco, Priscilla K Brastianos, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 113) with videos related to
Sort By:
Page
of 12
HIV Clinical Trials
|
February 11, 2003
Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy
Don E Smith, Jeff Hudson, Allison Martin, et al.
Pediatric Neurosurgery
|
December 18, 2023
A Case Report of Infant-Type Hemispheric Glioma with a Novel GAB1-ABL2 Kinase Fusion Treated with Dasatinib
Emery Buckner-Wolfson, Geena Jung, Timothy Kim, et al.
Lung
|
November 8, 2022
Validation and Meaningful Change Thresholds for an Objective Cough Frequency Measurement in Chronic Cough
Jonathan Schelfhout, Allison Martin Nguyen, Surinder S Birring, et al.
European Urology
|
August 7, 2023
Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review
Robert J Motzer, Pratik P Rane, Todd L Saretsky, et al.
Antiviral Therapy
|
March 9, 2005
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy
Jason C Kovacic, Allison Martin, Dianne Carey, et al.
Lancet (London, England)
|
February 14, 2004
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial
Andrew Carr, Cassy Workman, Dianne Carey, et al.
JAMA
|
July 4, 2002
Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial
Andrew Carr, Cassy Workman, Don E Smith, et al.
Metabolism: Clinical and Experimental
|
January 20, 2012
Energy content of weight loss: kinetic features during voluntary caloric restriction
Steven B Heymsfield, Diana Thomas, Corby K Martin, et al.
AIDS (London, England)
|
August 8, 2013
Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy
Allison Martin, Cecilia Moore, Patrick W G Mallon, et al.
European Urology Focus
|
January 10, 2018
The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort
Maxine Sun, Guillermo De Velasco, Priscilla K Brastianos, et al.
Page
of 12